Global Raltegravir Market 2020-2029

                                          
Introduction to Raltegravir


Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

Since the beginning of the epidemic, 76 million people have been infected with the HIV virus and about 33 million people have died of HIV/AIDS. Globally, 38.0 million [31.6–44.5 million] people were living with HIV at the end of 2020. An estimated 0.7% [0.6-0.9%] of adults aged 15–49 years worldwide are living with HIV, although the burden of the epidemic continues to vary considerably between countries and regions. The African region remains most severely affected, with nearly 1 in every 25 adults (3.7%) living with HIV and accounting for more than two-thirds of the people living with HIV worldwide. 690,000 people died of HIV-related illnesses worldwide in 2019.

With nearly 160 000 people newly diagnosed with HIV, 2017 marked another year of alarming numbers of new HIV diagnoses in the WHO European Region. Encouragingly, the overall increasing trend is not as steep as before. The eastern part of the Region recorded over 130 000 new HIV diagnoses, the highest number ever. On the other hand, the European Union and European Economic Area (EU/EEA) countries reported a decline in rates of new diagnoses, mainly driven by a 20% decrease since 2015 among men who have sex with men.

Despite significant advances in antiretroviral therapy (ART), which have led to dramatic decreases in patient morbidity and mortality, there remains no cure for HIV. In addition, the presence of naturally acquired and transmitted resistance to all currently available antiretroviral classes has limited available treatment options for patients living with the condition. It is estimated that as many as 18% of treatment naïve patients are resistant to at least one type of antiretroviral drug and as treatment experience progresses, as many as 76% of patients harbor viruses resistant to currently available medications. As such, there remains a need for the development of novel antiretroviral therapies that overcome current resistance patterns and treatment-related adverse events, allowing patients to remain virologically suppressed.

Integrase is one of three essential HIV-1 specific enzymes encoded by the human immunodeficiency virus that catalyzes the insertion of viral double-stranded complementary DNA into the host cells' genome. Drugs that inhibit integrase block the incorporation of HIV-1 complementary DNA into the host cell, inhibiting the replication of HIV. The United States Food and Drug Association (FDA) has approved two integrase strand transfer inhibitors (ISTI), raltegravir, and elvitegravir.

Raltegravir is an antiviral medicine that prevents human immunodeficiency virus (HIV) from multiplying in your body. Raltegravir is used to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). Raltegravir is not a cure for HIV or AIDS. It is for use in adults and children who weigh at least 4.4 pounds (2 kilograms).

This report studies the global Raltegravir market status and forecast, categorizes the global Raltegravir market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia).

The major manufacturers covered in this report

 	
REMEDYREPACK INC.
 	
Merck Sharp & Dohme Corp.
 	
Nucare Pharmaceuticals, Inc.
 	
A-S Medication Solutions
 	
RedPharm Drug, Inc. (U.S.A)
 	
Avera McKennan Hospital
 	
Cipla Ltd
 	
Facmed Pharmaceuticals Pvt. Ltd
 	
Jinan Chenghui-Shuangda Chemical Co., Ltd. (China)
 	
Merck Frosst Canada Ltd
 	
Actavis Pharma Company
 	
Aphena Pharma Solutions Tennessee, Inc.
 	
A-S Medication Solutions
 	
Astra Zeneca
 	
AstraZeneca Pharmaceuticals LP
 	
Avera McKennan Hospital
 	
Bryant ranch prepack
 	
Cardinal Health
 	
Carilion Materials Management
 	
Cobalt Laboratories
 	
H.J. Harkins Company
 	
Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc
 	
Lake Erie Medical Dba Quality Care Produts Llc
 	
Mantra Pharma Inc
 	
Med Health Pharma LLC.
 	
Mesource Pharmaceuticals
 	
Nora Pharma Inc
 	
PD-Rx Pharmaceuticals, Inc.
 	
Pharmaris Canada Inc
 	
Physicians Total Care, Inc.
 	
Pro Doc Limitee
 	
Qd Pharmaceuticals Ulc
 	
Ranbaxy Inc.
 	
Rebel Distributors
 	
Remedy Repack
 	
REMEDYREPACK INC.
 	
Sanis Health Inc
 	
Sivem Pharmaceuticals Ulc
 	
Sun Pharmaceutical Industries, Inc.

 

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

 	
Tablet
 	
Oral powder

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share, and growth rate for each application, including

 	
Hospital
 	
Drug store
 	
Others

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering

 	
North America
 	
Europe
 	
China
 	
Japan
 	
Southeast Asia
 	
India

We can also provide the customized separate regional or country-level reports, for the following regions:
North America

 	
United States
 	
Canada
 	
Mexico

Asia-Pacific

 	
China
 	
India
 	
Japan
 	
South Korea
 	
Australia
 	
Indonesia
 	
Singapore
 	
Rest of Asia-Pacific

Europe

 	
Germany
 	
France
 	
UK
 	
Italy
 	
Spain
 	
Russia
 	
Rest of Europe

Central & South America

 	
Brazil
 	
Argentina
 	
Rest of South America

Middle East & Africa

 	
Saudi Arabia
 	
Turkey
 	
Rest of Middle East & Africa

The study objectives of this report are:

To analyze and study the global Raltegravir capacity, production, value, consumption, status (2013-2017) and forecast (2020-2029);
Focuses on the key Raltegravir manufacturers, to study the capacity, production, value, market share, and development plans in the future.
Focuses on the global key manufacturers, to define, describe, and analyze the market competition landscape, SWOT analysis.
To define, describe, and forecast the market by type, application, and region.
To analyze the global and key regions' market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Raltegravir are as follows:
History Year: 2014-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

 	
Key Stakeholders
 	
Raltegravir Manufacturers
 	
Raltegravir Distributors/Traders/Wholesalers
 	
Raltegravir Subcomponent Manufacturers
 	
Industry Association
 	
Downstream Vendors